← All trials
NCT03482362
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2018
- Primary completion
- Dec 1, 2019
- Completion date
- Mar 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 82
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Netherlands Cancer InstituteLead sponsor
- Eli LillyCollaborator
- Katholieke Universiteit LeuvenOverall official - principal investigator
- Universidad Autonoma de BarcelonaCollaborator
- University of TurinCollaborator
- University of AmsterdamOverall official - principal investigator
- Katholieke Universiteit LeuvenCollaborator
- European Organisation for Research and Treatment of CancerCollaborator
- University of Campania Luigi VanvitelliCollaborator
- University of ValenciaCollaborator
- AgendiaCollaborator
- AgendiaOverall official - principal investigator
- Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, MilanoCollaborator
- Catalan Institute of HealthCollaborator
- INCLIVAOverall official - principal investigator
- Universidad Autonoma de BarcelonaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.